You are here

Primary Hyperoxaluria

Biotech’s important clinical data readouts

Biotech’s important clinical data readouts

EP Vantage

spinal muscular atrophy

Primary Hyperoxaluria

Flag link:

FDA approves Alnylam's first-ever drug for rare kidney disease

FDA approves Alnylam's first-ever drug for rare kidney disease

Bizjournals

Primary Hyperoxaluria

Flag link:

Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial

Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial

BioSpace

clinical trials

Primary Hyperoxaluria

Flag link:

Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1

Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1

Pharmaceutical Business Review

Primary Hyperoxaluria

Flag link:

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

clincial trials

Primary Hyperoxaluria

Flag link:

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

EP Vantage

Primary Hyperoxaluria

Flag link:

Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

Pharmaceutical Business Review

Dicerna Pharmaceuticals

breakthrough therapy

Primary Hyperoxaluria

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

CP Wire

Primary Hyperoxaluria

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Primary Hyperoxaluria

Flag link: